Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Sunday, October 11, 2015

Tried-and-True Antibiotic May Block Conversion to MS

Minocycline seemed to reduce progression to multiple sclerosis after first demyelinating event

BARCELONA -- After a first demyelinating event, a broad-spectrum tetracycline antibiotic may prevent conversion to multiple sclerosis (MS), researchers reported here.

In a phase III multicenter Canadian study, patients randomized to minocycline had a significant 44.6% relative risk reduction in progressing to MS over 6 months, reported Luanne Metz, MD, of the University of Calgary, at the European Committee for the Treatment and Research in Multiple Sclerosis meeting.

"We feel that this should be considered a treatment for MS," Metz said. "If you treat people with a simple prescription, you don't need to do complex paperwork or get insurance going. It's a well tolerated drug that requires no safety monitoring whatsoever."

She said she believes a typical regimen of the drug would cost $500 to $600 annually in Canada (about $387 to $460 U.S).

Current therapies work better if they're given to patients soon after their first clinical demyelinating event. However, insurance coverage for therapies varies by country and region, which may result in treatment delays until patients have a second clinical attack.

In addition, currently available oral therapies may not be ideal because of safety concerns.

Minocycline is an oral antibiotic with a recognized safety profile, widely available, and can be obtained in a lower-cost generic formulation, Metz said. It has many immune-modulating properties, including blocking the transmigration of leukocytes and reducing the activity of activated microglia, she noted.


MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here

No comments: